Skip to main content

Generics

  • E-prescribing of generics may be limited by pending legislation

    NEW YORK — Bills introduced in the legislatures of nearly a dozen states have pharmacy benefit managers and the generic drug industry fearing that the bills could lead to limits on doctors’ abilities to prescribe generics through e-prescribing.

    The Pharmaceutical Care Management Association, the main lobby for PBMs, said the bills would prohibit doctors from seeing lower-cost drug options, including generics and preferred brands; would prevent the e-prescribing software from showing safety information; and would disallow lower-cost pharmacy options.

  • FDA approves Quixin generic

    AMITYVILLE, N.Y. — The Food and Drug Administration has approved Hi-Tech Pharmacal’s generic version of a drug for eye infections.

    Hi-Tech announced the approval of levofloxacin ophthalmic solution in the 0.5% strength, a treatment for bacterial conjunctivitis. The company plans to launch next month.

    The drug is a generic version of Vistakon’s Quixin, which had sales of $2 million in 2010, according to IMS Health.

  • Court: Watson's generic OTC decongestant does not infringe on branded versions

    MORRISTOWN, N.J. — Over-the-counter generic versions of a line of products used to treat congestion do not infringe on the patents covering the branded versions, a federal court ruled Wednesday.

  • Actavis OKed to market generic Protonix

    MORRISTOWN, N.J. — Actavis has received approval from the Food and Drug Administration to market a generic version of a popular gastroesophageal reflux disease treatment.

    The generic drug maker said it would market pantoprazole sodium delayed-release tablets in the 20-mg and 40-mg strengths. The drug is the generic equivalent of Pfizer's Protonix, which had U.S. sales of approximately $1.6 billion for the 12 months ended Dec. 31, 2010, according to IMS Health.

    Actavis said it would distribute the drug soon.

  • Report: Sandoz has as many as 10 follow-on biologics in works

    NEW YORK — Sandoz is developing as many as 10 new follow-on biologics, according to published reports.

    Reuters, citing an interview with Sandoz head Jeff George in the German newspaper Handelsblatt, said the generics arm of Swiss drug maker Novartis had eight to 10 new biosimilar molecules in development.

  • Teva reports Q4, full-year results

    JERUSALEM — Drug maker Teva on Tuesday said its North American sales during the fourth quarter ended Dec. 31 drove the drug maker's financial well-being.

  • FDA approves Hospira's generic Hycamtin

    LAKE FOREST, Ill. — The Food and Drug Administration has approved a generic cancer drug from Hospira.

    The drug maker announced the approval of topotecan injection for treating small-cell lung cancer sensitive disease after first-line chemotherapy has failed.

    The drug is a generic version of GlaxoSmithKline’s Hycamtin, which had sales of more than $140 million in 2010, according to Hospira.

  • Elite granted FDA approval for generic Adipex-P

    NORTHVALE, N.J. — The Food and Drug Administration has approved a generic weight-loss drug made by Elite Pharmaceuticals.

    Elite announced Friday the approval of phentermine hydrochloride in the 37.5-mg strength, a generic version of Teva’s Adipex-P.

    Branded and generic versions of the drug had sales of around $40 million in 2010, according to Elite.

X
This ad will auto-close in 10 seconds